Compare LEE & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | ASBP |
|---|---|---|
| Founded | 1890 | 2021 |
| Country | United States | United States |
| Employees | 2500 | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 18.9M |
| IPO Year | N/A | N/A |
| Metric | LEE | ASBP |
|---|---|---|
| Price | $3.57 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.5K | ★ 56.6M |
| Earning Date | 11-26-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $562,341,000.00 | $1,941.00 |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.70 | $0.07 |
| 52 Week High | $16.84 | $15.80 |
| Indicator | LEE | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 34.55 | 38.18 |
| Support Level | $3.90 | $0.07 |
| Resistance Level | $4.43 | $0.11 |
| Average True Range (ATR) | 0.38 | 0.01 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 0.00 | 75.86 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.